SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " protalix " 5 found 🔀 AI-powered Shuffle
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up...
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2...
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for...
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for...
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and...